Summary: A large international study confirms that the blood biomarker phosphorylated tau 217 (p-tau217) provides long-term prognostic information about the risk of developing cognitive impairment. Cognitively normal individuals with very high baseline p-tau217 levels faced an absolute 38% risk of cognitive impairment within five years and a 78% risk within ten years. These risk estimates were independent of amyloid PET findings and APOE4 genetic status, making p-tau217 a validated tool for identifying high-risk candidates for Alzheimer’s prevention trials.
The findings support the use of p-tau217 as a screening tool in research and trial recruitment, while clinical guidance for asymptomatic individuals remains focused on lifestyle and preventive care until effective disease-modifying treatments are available.
Key Facts
- 5- and 10-year risk estimates: Researchers converted plasma p-tau217 measurements into individualized risk forecasts. Cognitively unimpaired older adults with very high baseline p-tau217 showed a 38% absolute risk of developing cognitive impairment within five years and a substantially higher risk—about 78%—over ten years.
- Independent prognostic value: The predictive strength of p-tau217 held even when adjusting for other established risk factors, including amyloid-beta PET signal and APOE4 genotype.
- Current clinical recommendations: Experts caution that routine testing of asymptomatic, healthy people is not yet recommended. At present, there are no approved disease-modifying therapies for preclinical Alzheimer’s, so test results generally do not change standard medical management.
- Practical clinical advice: For individuals identified as higher risk, recommended actions remain preventive and behavioral: regular cardiovascular exercise, balanced nutrition, prioritized sleep, and attention to metabolic and cardiovascular health.
- Long-term goal: Investigators aim to develop p-tau217 testing into a routine neurological screening—analogous to cholesterol testing—to guide long-term monitoring and early intervention strategies if effective therapies become available.
- Primary research use: The immediate application for p-tau217 testing is low-cost, rapid screening to recruit ideal participants for clinical trials of disease-modifying therapies, allowing treatments to be tested in people at high risk before symptoms begin.
Source: Mass General Brigham
A blood test measuring phosphorylated tau 217 (p-tau217) recently received federal clearance, raising questions about how well such tests forecast future cognitive decline in people who are currently cognitively healthy. An international team led by researchers at the Mass General Brigham Neuroscience Institute pooled data across six longitudinal cohorts to evaluate that prognostic value.
Their pooled analysis included 2,684 cognitively unimpaired older adults from studies in North America, Japan, and Australia. Baseline plasma p-tau217 was measured and most participants underwent amyloid PET at enrollment. Annual follow-ups assessed cognitive status over a median of 5.4 years and up to a maximum follow-up of 13.5 years. During follow-up, 478 participants progressed to cognitive impairment.
Results were presented at the Alzheimer’s Association International Conference and published in JAMA.
“We do not yet have disease-modifying treatments for people who discover they are at higher risk for Alzheimer’s disease before symptoms appear,” said Reisa Sperling, MD, senior and corresponding author and neurologist at the Mass General Brigham Neuroscience Institute. “That is why we do not recommend widespread blood testing for asymptomatic people at this time. Regardless of a test result, current medical advice remains: exercise regularly, eat a healthy diet, prioritize sleep, and manage overall metabolic and cardiovascular health.”
Sperling added that the role of p-tau217 could change rapidly if prevention trials demonstrate benefit. In that scenario, accurate blood-based risk measures could identify people who might benefit most from early interventions, much like cholesterol testing helps guide cardiovascular prevention.
Lead author Rachel F. Buckley, PhD, emphasized the study’s novelty: “We harmonized data across six cohorts to estimate an individual’s risk of progressing to cognitive impairment based on plasma p-tau217. Even with diverse samples and differing study designs, the association between higher p-tau217 and risk remained consistent.”
Statistically, each 1-standard-deviation increase in baseline p-tau217 was associated with a higher hazard of progression (adjusted hazard ratio ~1.32–1.38). Participants categorized as “high” and “very high” p-tau217 experienced estimated absolute risks of about 24% and 38% respectively over five years, with substantially larger risk estimates across ten years, though long-term estimates were limited by smaller sample sizes at later timepoints. Elevated p-tau217 was also linked to faster decline on cognitive composites.
The investigators note important limitations: the pooled sample derives from selected cohorts, which may introduce selection bias, and findings emphasize relatively short- to mid-term risk rather than lifetime risk. Further validation in broader, more representative populations and longer follow-up will improve individualized risk estimates and inform clinical decision-making.
“For now, p-tau217 is a powerful tool to identify people most suitable for prevention trials,” Sperling said. “As trials progress and if disease-modifying therapies succeed, individualized biomarker-based risk estimates could guide earlier treatment and monitoring.”
Authorship: Key authors include Reisa Sperling, Rachel F. Buckley, Aaron P. Schultz, Annie Li, Brian Healy, Diana L. Townsend, Colin J. Birkenbihl, Madison Cuppels, Gillian T. Coughlan, Mabel T. Seto, Jane A. Brown, Michael J. Properzi, Merle C. Hönig, Aaron P. Schultz, Jasmeer Chhatwal, Hyun-Sik Yang, Steven Arnold, Pia Kivisäkk, Brian Healy, Jorge Garcia Condado, Wai-Ying Wendy Yau, Michelle Farrell, Rebecca E. Amariglio, Dorene M. Rentz, Kathryn V. Papp, Keith A. Johnson, Bryan D. James, Sid O’Bryant, Robert A. Rissman, Melissa Petersen, Jessica Z. K. Caldwell, Tobey Betthauser, Julie Elisabeth Oomens, Maria Carrigan, Sterling C. Johnson, Oliver Langford, Ron Brookmeyer, Timothy J. Hohman, Michael Donohue, Paul S. Aisen, and many collaborators across the contributing studies.
Disclosures: Rachel Buckley reported NIH funding. Reisa Sperling reported NIH grants and other research and consulting relationships, including public-private trial funding; additional disclosures appear in the JAMA paper’s disclosures section.
Funding: The study received support from multiple sources, including the National Institutes of Health, the U.S. Department of Defense, Eli Lilly, the Alzheimer’s Association, the GHR Foundation, Accelerating Medicines Partnership, private donors, and in-kind contributions from industry and academic partners. Specific grant numbers and supporting organizations are listed in the published paper.
Key Questions Answered
A: Phosphorylated tau 217 (p-tau217) is a protein fragment that rises in blood when Alzheimer’s pathology begins in the brain. Historically, detecting these changes required costly PET scans or spinal fluid collection. A validated blood test makes it feasible to screen larger populations at lower cost and with greater convenience.
Q: If the blood test predicts risk well, why shouldn’t healthy people get tested now?
A: The main reason is clinical utility: current medicine lacks approved treatments that can prevent Alzheimer’s in asymptomatic individuals. Receiving a high-risk result can cause distress without offering a proven intervention. Until preventive therapies are available, testing asymptomatic people is not routinely recommended.
Q: How does this study advance efforts to prevent Alzheimer’s?
A: By providing rigorous, time-specific absolute risk estimates tied to p-tau217 levels, the study enables efficient identification of high-risk, yet asymptomatic individuals for enrollment in prevention trials—accelerating the search for treatments that could stop cognitive decline before it starts.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed to prepare this summary.
- Additional context and explanation were added by editorial staff for clarity.
About this Alzheimer’s research news
Author: Noah Brown
Source: Mass General Brigham
Contact: Noah Brown, Mass General Brigham
Image credit: Neuroscience News
Original Research: “Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment,” published in JAMA (DOI: 10.1001/jama.2026.12556). The study integrates data from major longitudinal studies and clinical trials focused on preclinical Alzheimer’s disease, including the Alzheimer’s Disease Neuroimaging Initiative, A4, LEARN, Harvard Aging Brain Study, HABS-HD, and WRAP.
Abstract (Condensed)
Importance: Blood-based biomarkers—especially plasma p-tau217—reflect early Alzheimer’s pathology in cognitively unimpaired people, but robust absolute risk estimates across cohorts are needed.
Objective: Estimate absolute risk of progression to cognitive impairment and rates of cognitive decline based on baseline plasma p-tau217 among cognitively unimpaired older adults.
Design, Setting, and Participants: Harmonized longitudinal data from 2,684 cognitively unimpaired older adults across six cohorts in North America, Japan, and Australia, with enrollment beginning in 2004 and follow-up through 2025.
Main outcomes: Time to progression to cognitive impairment (MCI or dementia, or sustained Clinical Dementia Rating ≥0.5) and longitudinal change on a composite cognitive measure (PACC).
Results: Over a median 5.4-year follow-up, 478 participants progressed to cognitive impairment. Each 1-SD higher baseline p-tau217 increased risk (hazard ratio ~1.3–1.4). Five-year absolute progression risk was about 24% for “high” and 38% for “very high” p-tau217 groups; ten-year risk estimates were substantially larger but limited by fewer long-term observations. Higher p-tau217 also predicted faster cognitive decline.
Conclusions: Elevated plasma p-tau217 consistently associates with greater short- to mid-term risk of clinical progression and accelerated cognitive decline in selected cohorts of cognitively unimpaired older adults. Time-specific absolute risk estimates support p-tau217’s role in prognostic models and clinical trial design. Validation in broader, more representative populations and longer follow-up are needed to inform individual clinical decision-making.